全球阿兹海默症相关失智症市场规模、市场份额、趋势和成长分析报告（2026-2034）

阿兹海默症相关失智症市场预计将从 2025 年的 77.4 亿美元增长到 2034 年的 117.7 亿美元，2026 年至 2034 年的复合年增长率为 4.76%。

由于人口老化加剧和神经退化性疾病发生率上升，全球阿兹海默症相关失智症市场持续成长。公众意识的提高和早期诊断的普及促进了治疗率的提升。世界各国政府和医疗机构正优先增加研究经费，以应对日益严重的阿兹海默症全球负担。

医药领域的进步和疾病修正治疗的研发是推动市场成长的关键因素。临床试验和生物标记研究投入的增加正在拓展治疗选择。支持性的医疗保健政策和记忆护理中心的扩建也有助于提高患者获得医疗保健服务和药物的途径。

鑑于创新药物疗法和个人化治疗方案的持续研究，未来前景十分乐观。数位健康技术在早期检测和监测方面的日益普及有望改善患者预后。随着发展中地区医疗基础设施的不断完善，市场扩张也预计将进一步加速。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章：全球阿兹海默症相关失智症市场：依药物类别划分

• 市场分析、洞察与预测
• 胆碱能/胆碱酯酶（ChE）抑制剂
• Memantine
• 同时服用的药物（Memantine和多奈哌齐）
• 其他的

第五章：全球阿兹海默症相关失智症市场：依分销管道划分

• 市场分析、洞察与预测
• 医院药房
• 零售
• 线上销售

第六章：全球阿兹海默症相关失智症市场：按地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第七章 竞争情势

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第八章：公司简介

• 主要公司的市占率分析
• 公司简介
  • Merz Pharma
  • Novartis AG
  • AbbVie Inc
  • Pfizer Inc
  • Daiichi Sankyo Company
  • Limited
  • Ono Pharmaceutical Co. Ltd
  • Johnson & Johnson Services Inc
  • Eisai Co. Ltd
  • H. Lundbeck A/S
  • F. Hoffmann-La Roche Ltd

The Dementia Associated with Alzheimer's Disease Market size is expected to reach USD 11.77 Billion in 2034 from USD 7.74 Billion (2025) growing at a CAGR of 4.76% during 2026-2034.

The global dementia associated with Alzheimer's disease market is growing due to the rising aging population and increasing prevalence of neurodegenerative disorders. Improved awareness and early diagnosis are contributing to higher treatment rates. Governments and healthcare organizations are prioritizing research funding to address the growing burden of Alzheimer's disease globally.

Pharmaceutical advancements and the development of disease-modifying therapies are key drivers supporting market growth. Increased investment in clinical trials and biomarker research is improving treatment options. Supportive healthcare policies and expansion of memory care centers also enhance patient access to care services and medications.

Future prospects are promising with ongoing research into innovative drug therapies and personalized treatment approaches. Growing adoption of digital health technologies for early detection and monitoring is expected to improve patient outcomes. As healthcare infrastructure strengthens in developing regions, market expansion will likely accelerate further.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Drug Class

• Cholinergic/Cholinesterase (ChE) Inhibitors
• Memantine
• Combined Drugs (Memantine & Donepezil)
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail
• Online Sales

COMPANIES PROFILED

• Merz Pharma, Novartis AG, AbbVie Inc, Pfizer Inc, Daiichi Sankyo Company, Limited, Ono Pharmaceutical Co Ltd, Johnson Johnson Services Inc, Eisai Co Ltd, H Lundbeck AS, F HoffmannLa Roche Ltd
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL DEMENTIA ASSOCIATED WITH ALZHEIMER'S DISEASE MARKET: BY DRUG CLASS 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Drug Class
• 4.2. Cholinergic/Cholinesterase (ChE) Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Memantine Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Combined Drugs (Memantine & Donepezil) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL DEMENTIA ASSOCIATED WITH ALZHEIMER'S DISEASE MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Distribution Channel
• 5.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Retail Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Online Sales Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL DEMENTIA ASSOCIATED WITH ALZHEIMER'S DISEASE MARKET: BY REGION 2022-2034(USD MN)

• 6.1. Regional Outlook
• 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.2.1 By Drug Class
  • 6.2.2 By Distribution Channel
  • 6.2.3 United States
  • 6.2.4 Canada
  • 6.2.5 Mexico
• 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.3.1 By Drug Class
  • 6.3.2 By Distribution Channel
  • 6.3.3 United Kingdom
  • 6.3.4 France
  • 6.3.5 Germany
  • 6.3.6 Italy
  • 6.3.7 Russia
  • 6.3.8 Rest Of Europe
• 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.4.1 By Drug Class
  • 6.4.2 By Distribution Channel
  • 6.4.3 India
  • 6.4.4 Japan
  • 6.4.5 South Korea
  • 6.4.6 Australia
  • 6.4.7 South East Asia
  • 6.4.8 Rest Of Asia Pacific
• 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.5.1 By Drug Class
  • 6.5.2 By Distribution Channel
  • 6.5.3 Brazil
  • 6.5.4 Argentina
  • 6.5.5 Peru
  • 6.5.6 Chile
  • 6.5.7 South East Asia
  • 6.5.8 Rest of Latin America
• 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.6.1 By Drug Class
  • 6.6.2 By Distribution Channel
  • 6.6.3 Saudi Arabia
  • 6.6.4 UAE
  • 6.6.5 Israel
  • 6.6.6 South Africa
  • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

• 7.1. Recent Developments
• 7.2. Company Categorization
• 7.3. Supply Chain & Channel Partners (based on availability)
• 7.4. Market Share & Positioning Analysis (based on availability)
• 7.5. Vendor Landscape (based on availability)
• 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL DEMENTIA ASSOCIATED WITH ALZHEIMER'S DISEASE INDUSTRY

• 8.1. Top Companies Market Share Analysis
• 8.2. Company Profiles
  • 8.2.1 Merz Pharma
  • 8.2.2 Novartis AG
  • 8.2.3 AbbVie Inc
  • 8.2.4 Pfizer Inc
  • 8.2.5 Daiichi Sankyo Company
  • 8.2.6 Limited
  • 8.2.7 Ono Pharmaceutical Co. Ltd
  • 8.2.8 Johnson & Johnson Services Inc
  • 8.2.9 Eisai Co. Ltd
  • 8.2.10 H. Lundbeck A/S
  • 8.2.11 F. Hoffmann-La Roche Ltd